evipedia.ai
← Back

DFPP vs. TPE for Health & Longevity

Evidence Review created on 10/24/2026 using AI4L / Opus 5.5

Also known as: Double Filtration Plasmapheresis vs. Therapeutic Plasma Exchange, DFPP, Double Filtration Plasmapheresis, Double-Filtration Plasmapheresis, Cascade Filtration, Cascade Plasmapheresis, Membrane Differential Filtration, INUSpheresis, TPE, Therapeutic Plasma Exchange, Plasma Exchange, PE, PEX, PLEX, Plasmapheresis

Motivation

Therapeutic plasma exchange and double filtration plasmapheresis are two ways of cleaning blood plasma outside the body. In plasma exchange, a machine separates the plasma from the blood cells, discards it and replaces it with a protein solution. In double filtration, the separated plasma passes through a second filter that holds back large molecules, such as antibodies and cholesterol-carrying particles, and returns most of the smaller proteins to the body. Both draw interest as ways to clear substances from the blood that build up with age, illness or environmental exposure.

Both methods have decades of hospital use for antibody-driven and blood-fat disorders. Longevity interest grew from mouse experiments that joined the circulation of old and young animals, and later from experiments that diluted old plasma, to test whether factors in the blood drive aging. Private clinics now offer sessions aimed at biological age, cholesterol-carrying particles and environmental chemicals such as microplastics.

This review examines how the two methods differ in what they remove, what human evidence exists for each in healthy and older adults, how their risks compare, and which practical factors separate them, for adults weighing either procedure as part of a longevity strategy.

Benefits - Risks - Protocol - Conclusion

These sources give high-level overviews of double filtration plasmapheresis (DFPP, a two-filter method that discards large plasma molecules and returns albumin, the main plasma protein) and therapeutic plasma exchange (TPE, removal of plasma and its replacement with albumin solution) as apheresis (blood-component removal outside the body) for health and longevity.

Four items are listed because no further source met the bar of a substantial, topic-specific overview. No dedicated content on DFPP or TPE was found from Rhonda Patrick, Peter Attia, Chris Kresser or Life Extension Magazine: FoundMyFitness offers only a brief digest of a single apheresis study, Attia’s site search returns only passing apheresis mentions in cholesterol podcasts, Kresser’s only a guest’s brief plasmapheresis remarks in a general longevity interview, and Life Extension’s only a 2016 conference announcement briefly mentioning a planned plasma-exchange trial.

Grokipedia

  • Plasmapheresis

    Grokipedia has no dedicated DFPP article; this article, which treats plasmapheresis as synonymous with TPE, covers technique, indications, risks and the experimental plasma-dilution research in aging.

Examine

No Examine article on double filtration plasmapheresis, therapeutic plasma exchange or plasmapheresis exists. Examine.com covers supplements and nutrition and does not typically cover medical procedures.

ConsumerLab

No ConsumerLab article on double filtration plasmapheresis, therapeutic plasma exchange or plasmapheresis exists. ConsumerLab tests supplements and consumer health products and does not typically cover medical procedures.

Systematic Reviews

These meta-analyses cover lipid removal in familial hypercholesterolemia (inherited very high LDL cholesterol, LDL-C), Alzheimer’s disease, myasthenia gravis (an autoimmune muscle-weakness disease), antineutrophil cytoplasmic antibody (ANCA, autoantibodies that inflame small blood vessels) vasculitis, and citrate (a calcium-binding clot preventer) anticoagulation.

No systematic review compares DFPP with TPE directly or tests either for longevity outcomes in healthy adults; the comparative and longevity-specific benefit side is therefore unrepresented.

Mechanism of Action

Both procedures draw blood, separate plasma (the liquid part of blood) from cells by centrifuge or membrane, and keep the circuit from clotting with citrate or heparin (an injectable anticoagulant).

  • TPE: the separated plasma is discarded and replaced with 5% albumin or donor plasma. One plasma-volume exchange non-selectively removes about 65% of plasma components, from signaling proteins to antibodies and lipoproteins (fat-carrying particles) (Merck Manual Professional Edition). Its longevity rationale is “dilution”: lowering age-elevated signaling proteins so their production resets, as the Conboy laboratory, with TPE provider Kiprov, reported in old mice (Mehdipour et al.).
  • DFPP: the plasma passes a second “fractionator” membrane whose pores hold back large molecules, including immunoglobulin M (IgM, a large antibody), much immunoglobulin G (IgG, the main antibody), fibrinogen (a clotting protein), LDL and lipoprotein(a) (Lp(a), an inherited LDL-like particle), and return smaller ones, mainly albumin. Only the small discarded fraction needs replacing (Hirano et al.).
  • Competing explanations: dilution proponents describe a systemic reset. Skeptics note removed proteins are re-made within days to weeks, and DFPP returns small, albumin-bound molecules TPE discards; in a two-patient report, TPE cleared albumin-bound thyroid hormones better than DFPP (Gerbal et al.). Dilution findings may not transfer to DFPP.
  • Pharmacological properties: neither is a drug; the relevant kinetics are removal and rebound: fibrinogen partly recovers within about 38 hours (Jouve et al.), and complement proteins (immune-defense proteins) returned to baseline within a month after TPE in a Kiprov-co-authored series (Kim et al.).

Historical Context & Evolution

TPE entered hospital practice in the 1970s with continuous-flow centrifuges, initially to remove harmful antibodies and abnormal proteins; the American Society for Apheresis (ASFA) now grades indications in its guideline (Connelly-Smith et al.), and its members’ units are paid for performing apheresis. DFPP was developed in Japan to cut albumin and donor-plasma use, and spread across Japan, Taiwan, China and Europe for lipid disorders, transplantation and autoimmune disease (Hirano et al.).

Interest in healthy aging began with heterochronic parabiosis (surgically joining old and young mice), which rejuvenated old muscle and liver progenitor (tissue-repair precursor) cells (Conboy et al.). Commercial young-plasma infusions followed until the US Food and Drug Administration (FDA) warned in 2019 of “no proven clinical benefit” (FDA). The field then shifted from adding young factors to removing old ones: saline-albumin exchange in old mice reproduced several parabiosis effects (Mehdipour et al.), and the albumin maker Grifols funded the AMBAR trial in Alzheimer’s disease (Boada et al.).

Human aging data remain small: an uncontrolled series (Kim et al.) and a 2025 sham-controlled trial (Fuentealba et al.), both run with Kiprov’s commercial apheresis practice, reported favorable biomarker shifts, while a randomized plasma-donation study found epigenetic clocks (DNA-methylation estimates of biological age) moved the other way (Borsky et al.). DFPP entered longevity marketing more recently, through INUSpheresis clinics and microplastic-removal claims from authors affiliated with INUS Medical Center (Bornstein et al.). Neither the “dilution” view nor its critiques has been settled by outcome trials.

Expected Benefits

High 🟩 🟩 🟩

Survival in Acute Liver Failure ⭕️ Not Central to Health & Longevity

It bears on a critical-care indication, not aging. Randomized trials from two independent groups, Larsen et al. (182 patients in Denmark, the UK and Finland; three days of high-volume TPE with donor plasma) and Maiwall et al. (40 patients in India; standard-volume TPE), found better transplant-free survival with TPE, which both attribute partly to dampened inflammation. Meta-analyses (Beran et al.; Sithamparapillai et al.) report the same survival signal. DFPP is untested here.

Magnitude: Hospital survival 58.7% with TPE vs 47.8% with standard medical therapy (hazard ratio [HR, the relative rate of an event over time] 0.56, stratified for liver transplantation; 95% confidence interval [CI, the range likely to contain the true value] 0.36–0.86) (Larsen et al.); 21-day transplant-free survival 75% vs 45% with standard medical therapy (HR 0.30; 95% CI 0.01–0.88) (Maiwall et al.); pooled 30-day survival relative risk (RR, risk in the treated group divided by risk in controls) 1.41 (95% CI 1.06–1.87) vs standard therapy (Beran et al.); mortality at 60 days or less RR 0.64 (95% CI 0.51–0.80) (Sithamparapillai et al.).

Medium 🟩 🟩

Slower Functional Decline in Alzheimer’s Disease ⚠️ Conflicted

In the sham-controlled AMBAR trial (Boada et al.) of 347 people with mild-to-moderate Alzheimer’s disease, pooled TPE arms slowed decline in daily function, confined to moderate disease; no single arm was significant alone. Grifols, which makes the albumin used, sponsored it. DFPP is untested here. A meta-analysis (Fei et al.) found no significant cognitive benefit but pooled mostly immunoglobulin trials. Net, one industry-funded, unreplicated trial supports a modest TPE effect in established disease.

Magnitude: 3.5 points less decline than sham on the daily-living scale at 14 months (95% CI 0.4–6.6; P = .03, where P is the probability of a difference this large arising by chance), reported as 52% less decline; cognitive scale difference −2.1 points (95% CI −4.4 to 0.2; P = .06; lower is better), not significant (Boada et al.).

Control of Antibody-Driven Disease, Comparable With DFPP and TPE ⭕️ Not Central to Health & Longevity ⚠️ Conflicted

It bears on antibody-driven diseases, not aging. A meta-analysis of randomized trials, mostly from one network, found plasma exchange lowers 12-month kidney failure in ANCA vasculitis (Walsh et al.). Comparing modalities, a randomized crossover study in chronic inflammatory demyelinating polyneuropathy (CIDP, an autoimmune nerve disease; Moranne et al.) and an anti-glomerular basement membrane nephritis (antibody attack on kidney filters) cohort (Liu et al.) found no difference, while Lyu et al. found faster Guillain-Barré syndrome (acute autoimmune nerve paralysis) improvement with TPE. Net, both control these diseases; TPE acts slightly faster.

Magnitude: End-stage kidney disease at 12 months, RR 0.62 (95% CI 0.39–0.98) with plasma exchange vs none, an absolute reduction of 0.08% to 16.0% depending on baseline risk (Walsh et al.); disability scores improved 1.3 points with TPE vs 0.8 with DFPP (P < 0.05), with no 6-month difference (Lyu et al.); odds ratio (OR, the relative odds of an outcome between groups) 0.23 for death or dialysis with DFPP vs TPE (95% CI 0.04–1.37), not significant (Liu et al.).

Low 🟩

Lower LDL Cholesterol and Lipoprotein(a)

DFPP is an established lipoprotein-apheresis method; a meta-analysis (Derakhshani et al.) found the largest pooled LDL-C reductions with DFPP, no technique difference for Lp(a) and no TPE comparison. Evidence is before–after and indirect in dose: lipid patients have weekly sessions, unlike occasional longevity use, and levels rebound between sessions.

Magnitude: Pooled LDL-C reduction of 281.82 mg/dL with DFPP in familial hypercholesterolemia (before–after, no control group) (Derakhshani et al.); a German registry, run by apheresis centers that bill for the procedure, reported 73% fewer major coronary events in the first two years of regular apheresis than in the two years before (no control group) (Schettler et al.).

Lower Circulating PFAS and Microplastics ⚠️ Conflicted

Uncontrolled studies report lower PFAS (per- and polyfluoroalkyl substances, persistent industrial chemicals) after DFPP and lower microplastics after TPE (Weinstein et al., Circulate Health-affiliated). Plasma donation, an indirect proxy, also lowered them. A DFPP pilot found no lasting PCB (polychlorinated biphenyls, banned industrial chemicals) reduction. Net, durable removal is unproven.

Magnitude: Plasma donation every 6 weeks lowered serum perfluorooctane sulfonate (PFOS, the main PFAS measured) by 3.1 ng/mL more than observation over 12 months (95% CI 2.4–3.8) (Gasiorowski et al.); DFPP lowered PFOS two weeks after treatment (no control group) (Liu et al.); TPE reductions in microplastics were reported only as a direction, with no outcome figure in the abstract (Weinstein et al.); PCB levels returned to baseline between weekly DFPP sessions (Gube et al.).

Speculative 🟨

Lower Epigenetic Biological Age ⚠️ Conflicted

A 42-person sham-controlled trial (Fuentealba et al., Kiprov- and Circulate-affiliated) found transient epigenetic clock reductions with TPE, largest with immunoglobulin; plasma donation raised clocks (Borsky et al.). Net, the signal is inconsistent.

Immune and Inflammatory Profile Shifts

Uncontrolled series report a lower neutrophil-to-lymphocyte ratio (a blood-count inflammation index) after DFPP (Castillo-Aleman et al.) and fewer inflammatory proteins after TPE with immunoglobulin (Kim et al.). Both groups have commercial apheresis ties.

Multi-Tissue Rejuvenation in Old Mice

Replacing half of old mice’s plasma with saline-albumin improved muscle repair, liver fibrosis (scarring) and new nerve-cell formation in a memory region (Mehdipour et al.). Evidence is animal-only; DFPP is untested.

Benefit-Modifying Factors

  • Genetic polymorphisms: LPA gene variants (the gene encoding Lp(a)’s protein) set lifelong Lp(a) levels; registry patients with isolated high Lp(a) showed larger event reductions with apheresis (Schettler et al.). No genotype has been studied as a modifier of TPE effects.
  • Baseline biomarkers: A descriptive post hoc (after-the-fact) analysis suggested a possible pattern of larger PFOS falls with plasma donation in people starting with the highest levels (Gasiorowski et al.); baseline routine labs only modestly predicted clock responders to TPE (Fuentealba et al.).
  • Sex: No sex-specific benefit analyses exist; the head-to-head CIDP study enrolled only men (Moranne et al.), and the PFAS trial was 98% male (Gasiorowski et al.).
  • Pre-existing conditions: In AMBAR, primary-endpoint benefit appeared only in moderate, not mild, Alzheimer’s disease (Boada et al.). Lipid benefit is confined to people with high LDL or Lp(a) despite maximal medication.
  • Age: TPE-related falls in protein noise (variability of protein levels, the study’s biological-age measure) appeared steeper in people aged 60–70+ than in those aged 46–52 (Kim et al.), but this rests on eight uncontrolled participants.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Sessions mainly cause low blood pressure; citrate, allergic and catheter events are separate items. In AMBAR (Boada et al., Grifols-sponsored), events far exceeded sham, and the World Apheresis Association registry (Stegmayr et al.; its members perform apheresis) of 169,000+ procedures reports rare severe events. DFPP and TPE were similarly tolerated head-to-head (Moranne et al.; Chabannes et al.). A sham-controlled trial in healthy adults (Fuentealba et al.) recorded one mild reaction among completers and two discontinuations. Net, events are mostly mild and appear rarer in healthy adults than in older patients.

Magnitude: 16.9% of TPE procedures had at least one procedure-related adverse event vs 1.1% of sham procedures in the same phase (the abstract cites 0.7% for all sham procedures), and 20.1% of procedures via central vs 13.1% via peripheral access (Boada et al.); registry rates were 1.6 mild, 2.0 moderate and 0.20 severe events per 100 procedures (no control group) (Stegmayr et al.); one mild allergic reaction in 240 TPE procedures (0.42%) among healthy adults who completed the intervention, per the full-text Methods, whereas the abstract reports two adverse events requiring discontinuation, sham-group rate not reported (Fuentealba et al.).

Medium 🟥 🟥

Antibody Depletion and Serious Infections

TPE removes antibodies non-selectively, and DFPP removes less IgG per session (Moranne et al.). In a meta-analysis of randomized trials in ANCA vasculitis (Walsh et al.), plasma exchange increased serious infections; those patients also took immunosuppressants (immune-dampening drugs), so the excess in healthy adults is probably smaller. The pooled trials came largely from one collaborative vasculitis network. Non-selective removal also lowers vaccine-induced antibodies and other protective proteins; whether repeated longevity sessions impair vaccine protection is untested.

Magnitude: Serious infections at 12 months, RR 1.27 (95% CI 1.08–1.49) with plasma exchange vs none, an absolute increase of 2.7% to 13.5% depending on baseline risk (Walsh et al.); IgG fell 61% per session with TPE vs 41% with DFPP (Moranne et al.).

Depletion of Fibrinogen, Clotting Factors and Platelets

Both methods lower fibrinogen and platelets, transiently raising bleeding risk, especially with anticoagulants. A randomized crossover study (Moranne et al.) found larger drops with TPE than DFPP; its abstract reports a greater prothrombin-time (clotting-speed test) fall with TPE, but the full text shows only a non-significant trend (p = 0.08). Fibrinogen recovery depends on the interval between sessions (Jouve et al.).

Magnitude: Per session, fibrinogen fell 71% with TPE vs 66% with DFPP, and platelets 35% vs 23% (Moranne et al.); bleeding occurred in a pooled 2.0% of citrate-anticoagulated sessions (no control group) (Liu et al.).

Allergic Reactions, More Frequent With TPE

Hypersensitivity reactions (hives, itching, rarely anaphylaxis, a severe whole-body allergic reaction) arise mainly from replacement fluids, especially donor plasma. Because DFPP needs little replacement, it was associated with fewer allergic episodes than TPE in an anti-glomerular basement membrane nephritis cohort (Liu et al.). Albumin-only TPE in healthy adults is covered under procedure-related adverse events above.

Magnitude: Allergy episodes in 13.64% of DFPP-treated vs 42.86% of TPE-treated patients (P = 0.049) (Liu et al.).

Vascular Access Complications

Repeated sessions need two good arm veins or a central venous catheter, which adds infection and thrombosis (clot) risk. In a DFPP series for blistering skin disease, bacteremia (bloodstream infection) complicated 31% of courses and was associated with central venous catheter use (Ohata et al.).

Magnitude: Bacteremia in 13 of 42 DFPP courses (31.0%), more frequent in courses using a central venous catheter (p = .0005); no group without apheresis for comparison (Ohata et al.).

Low 🟥

Citrate binds calcium and magnesium, causing hypocalcemia (low blood calcium) with tingling and cramps. A meta-analysis of uncontrolled studies (Liu et al.) found these shifts, including hypomagnesemia (low blood magnesium), common, highest with membrane TPE; heparin-anticoagulated DFPP avoids citrate but carries heparin risks.

Magnitude: Pooled hypocalcemia in 17.9% (95% CI 2.3–42.5) and hypomagnesemia in 45.6% of citrate-anticoagulated sessions (no control group) (Liu et al.).

Loss of HDL Cholesterol With DFPP

DFPP’s fractionator also removes HDL (high-density lipoprotein, the “protective” cholesterol carrier), more than other apheresis techniques in a meta-analysis (Derakhshani et al.). Evidence is before–after only, and the clinical significance of transient HDL loss is unknown.

Magnitude: Pooled HDL cholesterol reduction of 15.75 mg/dL with DFPP (before–after, no control group) (Derakhshani et al.).

Heparin-Induced Thrombocytopenia

Heparin used in many DFPP circuits can trigger heparin-induced thrombocytopenia (HIT, an immune reaction that lowers platelets and causes clots). The evidence for DFPP is a single case report (Chen et al.).

Magnitude: Not quantified in available studies. Only a single case report describes HIT after DFPP (Chen et al.).

Microplastic Leaching From Tubing

Plastic apheresis tubing can shed microplastics back into the blood, offsetting removal when starting levels are low. The single study is uncontrolled and comes from a commercial TPE provider (Weinstein et al.).

Magnitude: Net microplastic reduction disappeared at low starting levels because of leaching; the abstract reports no outcome figure (Weinstein et al.).

Speculative 🟨

Faster Epigenetic Aging After Repeated Plasma Removal

In randomized plasma donors (Borsky et al.), repeated removal without replacement raised GrimAge, Hannum and DunedinPACE epigenetic clocks. Relevance to TPE or DFPP, which replace volume, is unknown, and clocks are unvalidated surrogates.

Risk-Modifying Factors

  • Genetic polymorphisms: Selective IgA deficiency (lack of immunoglobulin A, often inherited) with anti-IgA antibodies raises anaphylaxis risk when donor plasma is used; inherited clotting disorders such as factor V Leiden may raise catheter-clot risk. Both rest on mechanism rather than apheresis-specific studies.
  • Baseline biomarkers: Low starting fibrinogen, platelets, IgG or ionized calcium leave less reserve for per-session drops of 23–71% (Moranne et al.); fibrinogen recovery depends on the starting level and interval (Jouve et al.).
  • Sex: No sex-specific safety analyses exist. Smaller body size means smaller plasma volume, so fixed exchange volumes represent a larger fraction and veins may be harder to access.
  • Pre-existing conditions: Neurological diagnoses carried higher hypotension (low blood pressure) risk (Stegmayr et al.); ACE (angiotensin-converting enzyme) inhibitors (blood-pressure drugs that slow breakdown of bradykinin, a vessel-dilating peptide) cause atypical reactions (Owen & Brecher); heart failure and immunosuppression add risk.
  • Age: Older adults with mild-to-moderate Alzheimer’s disease tolerated TPE at rates similar to other indications, with more events through central catheters (Boada et al.). Frailty, low blood volume and fragile veins increase hypotension and access problems.

Key Interactions & Contraindications

  • ACE inhibitors (lisinopril, enalapril, ramipril): Avoid near sessions; all 14 TPE patients taking them had atypical flushing or hypotension reactions (Owen & Brecher), with reactions after doses within 48–72 hours (Weinstein). Mitigation: holding them at least 24 hours beforehand.
  • Monoclonal antibody drugs (lab-made antibody medicines: rituximab, natalizumab): TPE clears large antibody drugs efficiently (Ding et al.), and DFPP likely retains them too (theoretical). Consequence: lost drug effect. Mitigation: dosing after the session.
  • Highly protein-bound prescription drugs (phenytoin, valproate, warfarin): Removal is documented mostly in case reports (Ibrahim et al.); a systematic review found low phenytoin, variable valproate removal (Makhlouf et al.). Consequence: lower levels, breakthrough seizures. Mitigation: post-session dosing, level checks.
  • Anticoagulants and antiplatelet drugs (clot-preventing drugs: apixaban, clopidogrel): Fibrinogen and platelet depletion add to bleeding risk (theoretical). Mitigation: checking fibrinogen and platelets before sessions.
  • Antihypertensives and diuretics (blood-pressure-lowering and fluid-removing drugs: amlodipine, hydrochlorothiazide): Additive hypotension during fluid shifts (theoretical). Mitigation: holding the morning dose on session days, by prescriber decision.
  • Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, common pain-relieving drugs: ibuprofen, naproxen) and aspirin: Added puncture-site bleeding while fibrinogen is low (theoretical). Mitigation: avoiding them on session days.
  • Antiplatelet supplements (fish oil, vitamin E, ginkgo): Additive bleeding tendency (theoretical). Mitigation: pausing them around sessions.
  • Lipoprotein-carried supplements (coenzyme Q10, vitamin E, carotenoids): DFPP removes them with LDL, lowering levels (theoretical). Mitigation: taking them after sessions.
  • Calcium and magnesium supplements: Potentially beneficial; they offset citrate-related losses and tingling (theoretical). Mitigation: oral calcium is commonly given around citrate sessions.
  • Intravenous immunoglobulin (IVIG): Given after TPE in the 2025 trial, it adds immunoglobulin-specific risks, and IVIG given before a session would be removed (theoretical) (Fuentealba et al.).
  • Plasma or blood donation and vaccinations: Donation adds protein and IgG loss, and TPE removes vaccine-induced antibodies (theoretical). Mitigation: spacing donations and scheduling vaccines after a course.

Populations who should avoid DFPP vs. TPE:

  • People with active infection or active cancer (2025 trial exclusion criteria) (Fuentealba et al.)
  • People with symptomatic coronary artery disease, congestive heart failure, restrictive lung disease or asthma (same exclusion criteria) (Fuentealba et al.)
  • People with poor peripheral venous access for whom only a central catheter is possible (same exclusion criteria) (Fuentealba et al.)
  • People who cannot pause ACE inhibitors (Owen & Brecher)
  • People with prior heparin-induced thrombocytopenia, for heparin-anticoagulated DFPP (Chen et al.)
  • People with known allergy to albumin or plasma products
  • Pregnant people, outside a specific medical indication

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Holding ACE inhibitors: stopping them at least 24 hours before each session prevents flushing and hypotension (Owen & Brecher).
  • Peripheral veins over catheters: two arm veins instead of a central catheter lower procedure-related adverse events (13.1% vs 20.1%) (Boada et al.) and catheter bacteremia.
  • Albumin rather than donor plasma: 5% albumin replacement causes fewer reactions than donor plasma (Merck Manual Professional Edition), and DFPP, with its small replacement volume, had fewer allergic episodes than TPE (Liu et al.), limiting allergic reactions.
  • Calcium support with citrate: oral or intravenous calcium during citrate-anticoagulated sessions, with ionized calcium checks, targets the hypocalcemia found in 17.9% of such sessions (Liu et al.), limiting tingling and cramps.
  • Pre-session coagulation check: fibrinogen and platelets are measured before each session, and sessions are postponed if fibrinogen is below 1.0 g/L (100 mg/dL), the level below which plasma is commonly supplemented (Wodajo et al.), limiting bleeding risk.
  • Session spacing: intervals of at least 2–4 weeks between longevity sessions let fibrinogen recover (Jouve et al.), whereas IgG took about 12 weeks to return to baseline in plasma donors (Warner et al.), limiting cumulative bleeding and infection risk.
  • IgG monitoring: IgG is checked before repeat courses, and sessions are paused if it falls below 6 g/L, the threshold used to monitor plasma donors (Warner et al.), limiting infection risk.
  • Citrate instead of heparin after HIT: citrate anticoagulation in anyone with prior heparin-induced thrombocytopenia avoids re-exposure to heparin, the trigger in a reported DFPP case (Chen et al.), limiting the risk of recurrence.
  • Meal and fluids beforehand: a meal and about 500 mL of fluid in the 2 hours before a session reduce vasovagal (fainting-reflex) hypotension.
  • Experienced unit: an apheresis unit with emergency capability limits the consequences of rare severe reactions such as anaphylaxis.

Therapeutic Protocol

Other parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.

  • TPE, Kiprov/Circulate regimen: one plasma volume exchanged for 5% albumin by centrifuge, as two sessions in one week monthly for 3 months or one session monthly for 6 months; one arm added 2 g IVIG (Fuentealba et al.).
  • TPE, AMBAR regimen: six weekly conventional exchanges of about 2.4–2.7 L, then 12 monthly low-volume exchanges of about 0.7–0.9 L, with 20–40 g albumin, with or without IVIG (Boada et al.).
  • Lipoprotein apheresis regimen, including DFPP: weekly sessions for people with Lp(a) above 60 mg/dL and established cardiovascular disease, as in German practice (Parhofer et al., a trial sponsored by Novartis, maker of a competing drug).
  • DFPP, INUSpheresis regimen: at least two sessions with a plasma separator and TKM58 fractionator, used by INUS Medical Center authors in a chronic fatigue series (Bornstein et al.); two-session courses are used for lipids (Castillo-Aleman et al.).
  • DFPP volume and replacement: about 4.5 L plasma treated per session, with about 20 g albumin versus 180 g for TPE (Moranne et al.).
  • Competing approaches: dilution-oriented clinics favor TPE with albumin; lipid- and toxin-oriented clinics favor DFPP. Neither has outcome data in healthy adults, so neither is the default.
  • Time of day: no data favor a time; morning sessions allow post-session observation during the day.
  • Half-life: not a drug; removed proteins rebound, with fibrinogen partly recovering within about 38 hours (Jouve et al.) and complement back to baseline within a month (Kim et al.).
  • Single vs split sessions: in the 2025 trial, Systems Age clocks fell with monthly single but not paired weekly TPE sessions, while other clocks changed with paired sessions; no regimen was clearly superior (Fuentealba et al.).
  • Genetic polymorphisms: high Lp(a) from LPA variants is the main genetic reason to choose DFPP over TPE; no pharmacogenetic (gene-based drug-response) variants affect either procedure.
  • Sex: no sex-based dosing differences are reported; plasma volume is calculated from sex, height and weight.
  • Age: older or frail adults commonly receive smaller exchange volumes, as in AMBAR’s low-volume phase (Boada et al.).
  • Baseline biomarkers: high Lp(a) or LDL favors DFPP; low fibrinogen, IgG or calcium favors longer intervals or smaller volumes.
  • Pre-existing conditions: DFPP caused greater weight gain (1.0 vs 0.4 kg) per session (Moranne et al.), relevant in heart failure; ACE-inhibitor users need dose holds.

Discontinuation & Cycling

  • Lifelong or short-term: no defined duration exists for longevity use; trials ran 3–14 months (Fuentealba et al.; Boada et al.), while lipid apheresis for high Lp(a) is open-ended.
  • Withdrawal effects: no physiological withdrawal occurs; removed lipoproteins rebound between sessions, which is why lipid apheresis is weekly (Parhofer et al.).
  • Tapering: not required; AMBAR stepped down from weekly full exchanges to monthly low-volume exchanges (Boada et al.).
  • Cycling: clock reductions faded by the third time point despite continued TPE, suggesting compensation (Fuentealba et al.); no study shows that pauses restore effect.

Sourcing and Quality

  • Facility: hospital and accredited apheresis units offer physician oversight and emergency capability; commercial longevity clinics vary widely in staffing, devices and protocols.
  • Devices: TPE typically uses a centrifugal separator such as Spectra Optia (Fuentealba et al.); DFPP uses a plasma separator plus a fractionator such as the TKM58 filter (Bornstein et al.).
  • Replacement fluid: pharmaceutical-grade 5% human albumin is standard; donor plasma adds allergy and infection risk and is reserved for medical indications.
  • Immunoglobulin products: where IVIG is added, licensed products such as Octagam 10% were used in human aging studies (Kim et al.).
  • Disposables: single-use sterile circuits are standard; tubing may leach microplastics (Weinstein et al.).
  • Young-plasma infusions: the FDA has cautioned against for-profit young-donor plasma infusions (FDA).
  • Supplement testing: third-party supplement testing does not apply; quality depends on device approval, fluid source and staff training.

Practical Considerations

  • Time to effect: lipid and antibody reductions are immediate but rebound within days to weeks; the Alzheimer’s effect was measured at 14 months (Boada et al.), and clock changes appeared within weeks, then faded (Fuentealba et al.).
  • Common pitfalls: reading immediate post-session lab drops as lasting change; not pausing ACE inhibitors; attributing TPE-plus-immunoglobulin results to TPE alone; relying on clinic-run, unvalidated biomarker panels.
  • Regulatory status: DFPP lacks US FDA approval (Moranne et al.), aging is not an ASFA-graded indication (Connelly-Smith et al.; ASFA members perform apheresis), and lipoprotein apheresis is described as the only approved Lp(a) treatment (Parhofer et al.).
  • Cost and accessibility: a French hospital session cost about €942 for TPE vs €1,269 for DFPP (Moranne et al.); longevity sessions are self-paid at private clinics. Published DFPP experience comes mainly from Japan, China, Taiwan, Europe and the Gulf states.
  • Payer incentives: insurers pay only for medical indications, where the cheaper local modality may be favored; longevity use is self-paid, but payer preference for the cheaper modality could bias guidelines and research funding toward it.
  • Session time: about 3–3.5 hours, longer with peripheral veins (201 vs 177 minutes) (Moranne et al.).

Interaction with Foundational Habits

  • Sleep: None direct. Post-session fatigue or lightheadedness may curtail evening activity, but no study has measured sleep after DFPP or TPE. Being well rested before sessions may reduce vasovagal reactions.
  • Nutrition: Indirect. Eating and drinking beforehand reduces hypotension, and calcium-rich food offsets citrate losses. Adequate protein supports albumin and antibody re-synthesis. Diet influences how fast LDL rebounds, whereas Lp(a) is largely genetic; lowering PFAS and plastic intake limits re-accumulation after removal.
  • Exercise: Indirect. Strenuous training is usually skipped on session days because of hypotension and puncture-site bleeding. Exercise and DFPP both lower atherogenic (artery-clogging) lipids, a potentiating direction, but no study has tested them together.
  • Stress management: Indirect. Needle anxiety can trigger vasovagal fainting, which slow breathing and relaxation techniques may lessen. A DFPP study in chronic fatigue (Bornstein et al.) speculated on stress-hormone effects, but no study has measured cortisol after apheresis.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes reserve and identifies who is unsuitable: a complete blood count, fibrinogen and clotting tests, ionized calcium and magnesium, IgG, albumin and kidney function, plus lipids and Lp(a) when DFPP targets lipids. A medication review identifies ACE inhibitors, anticoagulants and antibody drugs.

Ongoing monitoring follows this cadence: blood count, fibrinogen and ionized calcium before every session during the first month, then before every second session; IgG before each new course and every 3 months during continued use; lipids and Lp(a) immediately before and after the first session, then every 3–6 months. Success is defined by the target chosen: sustained lipid lowering for DFPP, or a pre-specified biomarker change measured with the same laboratory and assay, never a single post-session value.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 150–450 × 10⁹/L (standard reference range) Safety: low counts delay sessions Fell 35% (TPE) vs 23% (DFPP) per session (Moranne et al.); draw pre-session
Fibrinogen 2.0–4.0 g/L (standard reference range) Safety: low levels delay sessions Fell 71% (TPE) vs 66% (DFPP) per session (Moranne et al.); recovery depends on interval (Jouve et al.); pair with prothrombin time
Prothrombin time/INR INR 0.8–1.2 (standard reference range) Safety: bleeding risk INR (international normalized ratio, a standardized clotting-time measure); essential with anticoagulants
Ionized calcium 1.15–1.35 mmol/L (standard reference range) Safety: citrate toxicity Check during or after citrate sessions (Liu et al.)
Magnesium 0.7–1.0 mmol/L (standard reference range) Safety: citrate losses Hypomagnesemia pooled at 45.6% of citrate sessions (Liu et al.)
IgG 7–16 g/L (standard reference range) Safety: low levels prompt longer intervals Fell 61% (TPE) vs 41% (DFPP) per session (Moranne et al.); re-check before each course
Albumin 35–50 g/L (standard reference range) Safety: DFPP lowers, TPE raises it Opposite direction by modality (Moranne et al.)
LDL-C Below 55–116 mg/dL depending on cardiovascular risk category, per ESC/EAS 2019 guideline (Mach et al.) Expected to change: DFPP lowers it ESC/EAS (European Society of Cardiology/European Atherosclerosis Society) targets (Mach et al.); the societies’ members include lipid specialists who use apheresis, though the targets apply to all lipid-lowering methods; conventional laboratory reference below 130 mg/dL; fasting not required; measure pre- and post-session
Lp(a) Below 30 mg/dL (below 75 nmol/L), per EAS 2022 consensus (Kronenberg et al.) Expected to change: DFPP lowers it Consensus risk cut-offs (Kronenberg et al.); the EAS panel included Parhofer, who leads lipoprotein apheresis trials (Parhofer et al.); conventional laboratory reference below 30 mg/dL; rebounds between sessions
Epigenetic clock age No established target; track change from own baseline with the same assay Expected to change: TPE may lower it Unvalidated surrogate; effects faded in the 2025 trial (Fuentealba et al.)
Serum PFOS/PFAS No established target; track change from own baseline Expected to change if removal is the goal Measure before and weeks after a course, not only immediately after (Gasiorowski et al.)

Qualitative markers:

  • Energy and fatigue in the days after each session
  • Lightheadedness, tingling or cramps during sessions
  • Bruising or soreness at puncture sites
  • Frequency of infections between courses
  • Cognitive clarity and exercise tolerance over months

Emerging Research

  • TPE for frailty (NCT07836127): a randomized study will compare plasma exchange plus albumin with or without IVIG in 34 frail adults, primary endpoint frailty score at 1 month; not yet recruiting, completion 2028. A positive result would add a functional signal; a null result would weaken the dilution case.
  • Open-label frailty plasmapheresis (NCT05054894): albumin-replaced plasmapheresis in 100 frail older adults, primary endpoint Clinical Frailty Scale change at 6 months. Registered completion May 2025 has passed; status unknown, no results posted. A positive result would suggest functional benefit, though uncontrolled; a null result would weaken the frailty rationale.
  • DFPP for microplastics and PFAS (NCT07658443): 20 adults already receiving DFPP, sponsored by Proxima Health, a commercial provider; paired pre/post measures. Registered completion September 2026 has passed; the registry still lists it as enrolling by invitation, with no results posted. Positive results would confirm acute removal; null results would undercut DFPP detoxification claims.
  • DFPP for cytokines, lipids and metals (NCT06224296): 250 adults, sponsored by Shanghai Cell Therapy Group. Registered completion March 2025 has passed; status unknown, no results posted. Positive six-month results would show DFPP effects outlasting the session; null results would confirm that changes are transient.
  • Lp(a) apheresis outcomes (NCT02791802): matched-pair comparison of apheresis versus maximal lipid therapy in 1,000 patients. Registered completion December 2022 has passed; status unknown, no results posted. A positive result would give DFPP-type apheresis its first controlled event evidence; a null result would undercut its cardiovascular rationale.
  • Young-donor plasma exchange (Søraas et al.): a 2026 12-patient pilot in mild cognitive impairment found exchange with young plasma feasible, with expected adverse events; the authors call for a larger controlled efficacy trial.
  • Clock evidence across interventions (Johnson & Sinclair): a 2026 review of 41 human studies lists plasmapheresis among interventions that accelerated next-generation clocks, a direction that could weaken the TPE case.
  • Drug alternatives for Lp(a) (Parhofer et al.): pelacarsen, an Lp(a)-lowering injection, cut apheresis need sharply in a 2026 randomized trial, which could displace DFPP for lipid indications.
  • Completed TPE aging trial (NCT06534450): registered completion August 2025; status not updated on the registry, but results were published (Fuentealba et al.) and are reported under Expected Benefits.

Conclusion

Plasma exchange and double filtration are both established hospital procedures that clean the blood’s liquid portion outside the body, but they work differently. Plasma exchange discards everything in the removed plasma and replaces it with a protein solution, while double filtration discards only large molecules, such as antibodies and cholesterol-carrying particles, and returns most smaller proteins.

For health-focused adults, neither method has shown a lasting clinical benefit in healthy people. Plasma exchange has the broader aging-related evidence: one industry-funded trial in Alzheimer’s disease and small, commercially linked studies of biological-age markers, with mixed and short-lived signals. Double filtration has the clearer cholesterol-particle effect, which matters most for people with inherited high levels, but much of its longevity and toxin-removal marketing rests on data from studies without comparison groups, run by clinics that sell it.

The risks are similar in kind: drops in blood pressure, tingling from the anti-clotting solution, loss of clotting proteins and antibodies, and problems with catheters. Plasma exchange removes more antibodies and clotting proteins and causes more allergic reactions, while double filtration preserves the body’s own main protein but removes some protective cholesterol.

The evidence base is small, short and often produced by parties who profit from the procedures, including clinic owners, a blood-protein manufacturer and a filter manufacturer. For this audience, the choice between the two rests on the specific target, and the size of any longevity benefit from either remains unknown.

Top - Benefits - Risks - Protocol